STAAR Surgical reported preliminary net sales of more than $90 million for the first quarter of 2026, a figure that more than doubles the $42.6 million recorded in the same period a year earlier.
The preliminary results cover the quarter ended April 3, 2026 and are based on unaudited data. When compared to the $57.8 million in net sales reported for the fourth quarter of 2025, the first‑quarter figure represents a 56 percent increase from the prior quarter.
Management attributes the jump to a strong rebound in China, the company’s largest market, and continued double‑digit growth in the Americas. The company also highlighted a significantly improved cost structure that is expected to lift adjusted EBITDA for the quarter.
Deborah Andrews, interim co‑CEO and CFO, said, “We are very pleased with our strong first quarter net sales in our largest market, China, which accounted for the majority of the increase in net sales, along with continued double‑digit growth in the Americas. Our higher net sales, combined with our significantly improved cost structure, are expected to drive a meaningful improvement in adjusted EBITDA for the first quarter. These results deliver on two of the three core objectives outlined in our Shareholder Letter earlier this year—Revenue Growth and Profit Expansion—and though early in the year, are indicators of the overall good health of our business.”
Analysts had expected Q1 2026 revenue of $67.2 million to $68 million. The preliminary figure therefore beats consensus estimates by roughly $22 million, or about 32 percent, underscoring the company’s stronger‑than‑anticipated execution.
The company has not issued forward revenue or earnings guidance, citing volatile global business conditions. It will release full audited results and file its Form 10‑Q in early May, providing a more comprehensive view of the quarter’s performance.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.